Caladrius Biosciences Inc (CLBS) was Initiated by Chardan Capital Markets to “Buy” and the brokerage firm has set the Price Target at $6.50. Chardan Capital Markets advised their investors in a research report released on Aug 23, 2016.
Caladrius Biosciences Inc closed down -0.02 points or -0.37% at $5.45 with 12,510 shares getting traded on Friday. Post opening the session at $5.4888, the shares hit an intraday low of $5.39 and an intraday high of $5.58 and the price fluctuated in this range throughout the day.Shares ended Friday session in Red.
In a different news, on Jul 5, 2016, Eric Wei (director) sold 87,500 shares at $0.61 per share price. According to the SEC, on Aug 18, 2015, David J Mazzo (CEO) purchased 20,000 shares at $1.40 per share price. On Aug 13, 2015, Robert S Vaters (CFO) purchased 12,385 shares at $1.35 per share price, according to the Form-4 filing with the securities and exchange commission.
Caladrius Biosciences Inc. formerly NeoStem Inc. is a clinical-stage biopharmaceutical company. The Company’s clinical program is based on its dendritic cell and cancer cell technology. It is focused on the development of a cancer treatment designed to focus the cells responsible for tumor growth and metastasis known as cancer or tumor initiating cells (CSCs). Its lead product candidate based on this platform technology is NBS20 (targeted cancer immunotherapy) which is in Phase II trials focuses on malignant melanoma as an initial indication. Its therapeutic platforms also include ischemic repair (CD34 Cell Program) and immune modulation (T Regulatory Cell Program). Its CD34 Cell Program develops therapies designed to address diseases and conditions caused by ischemia. Its product candidate in CD34 Cell Program is NBS10 which has completed Phase I clinical trials. Under T Regulatory Cell Program the Company is developing NBS03D which is in the Phase I clinical trial stage.